LENZ Therapeutics
LENZ
LENZ Therapeutics (LENZ) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.02
- EPS estimate
- −$1.05
- EPS surprise
- +2.90%
- Revenue surprise
- +130.76%
- Revenue
- $5.5M
- Revenue estimate
- $2.4M
- Reported
- Aug 11, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$1.05 | −$1.02 | +2.90% | $5.5M | SEC |
| Q1 2026 | May 11, 2026 | −$1.05 | −$1.32 | −25.99% | $1.9M | SEC |
| Q4 2025 | Mar 24, 2026 | −$0.91 | −$1.16 | −27.71% | $1.6M | SEC |
| Q3 2025 | Nov 5, 2025 | −$0.69 | −$0.59 | +14.78% | $12.5M | SEC |
| Q2 2025 | Jul 30, 2025 | −$0.61 | −$0.53 | +13.14% | $5.0M | SEC |
| Q1 2025 | May 7, 2025 | −$0.52 | −$0.53 | −2.26% | $0.00 | SEC |
| Q4 2024 | Mar 19, 2025 | −$0.41 | −$0.46 | −12.20% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.46 | −$0.38 | +17.07% | $0.00 | SEC |
| Q2 2024 | Aug 14, 2024 | −$0.48 | −$0.40 | +16.44% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$0.82 | −$3.53 | −330.49% | $0.00 | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.91 | −$2.58 | −182.97% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$6.79 | −$6.79 | +0.00% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$2.41 | −$3.01 | −25.00% | $0.00 | SEC |
| Q4 2022 | Mar 20, 2023 | −$3.45 | −$3.08 | +10.83% | $0.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$3.11 | −$3.15 | −1.29% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$3.44 | −$3.36 | +2.31% | $0.00 | SEC |
| Q1 2022 | May 12, 2022 | −$2.73 | −$3.36 | −23.08% | $0.00 | SEC |
| Q4 2021 | Mar 21, 2022 | −$2.08 | −$2.45 | −17.65% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$1.94 | −$1.96 | −1.20% | $0.00 | — |
| Q2 2021 | Aug 12, 2021 | −$2.03 | −$24.15 | −1089.66% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did LENZ Therapeutics (LENZ) last report earnings?
LENZ Therapeutics last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did LENZ beat earnings estimates?
Yes. LENZ Therapeutics reported EPS of −$1.02 for Q2 2026 against a −$1.05 estimate — a 2.90% beat.
How much revenue did LENZ report last quarter?
LENZ Therapeutics reported $5.5M in revenue for Q2 2026, against a consensus estimate of $2.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.